References
- Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008; 14:5967 - 76; http://dx.doi.org/10.1158/1078-0432.CCR-07-4535; PMID: 18829475
- Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006; 24:971 - 83; http://dx.doi.org/10.1038/nbt1235; PMID: 16900146
- Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 2009; 101:374 - 83; http://dx.doi.org/10.1093/jnci/djp001; PMID: 19276453
- Bates SE, Longo DL. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 1985; 12:163 - 207; http://dx.doi.org/10.1016/0305-7372(85)90037-4; PMID: 2416441
- Ligthart ST, Coumans FA, Attard G, Cassidy AM, de Bono JS, Terstappen LW. Unbiased and automated identification of a circulating tumour cell definition that associates with overall survival. PLoS One 2011; 6:e27419; http://dx.doi.org/10.1371/journal.pone.0027419; PMID: 22087312
- Dixon SC, Horti J, Guo Y, Reed E, Figg WD. Methods for extracting and amplifying genomic DNA isolated from frozen serum. Nat Biotechnol 1998; 16:91 - 4; http://dx.doi.org/10.1038/nbt0198-91; PMID: 9447601
- Gormally E, Caboux E, Vineis P, Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635:105 - 17; http://dx.doi.org/10.1016/j.mrrev.2006.11.002; PMID: 17257890
- Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368:1199 - 209; http://dx.doi.org/10.1056/NEJMoa1213261; PMID: 23484797